Aspergillus infections have become an important health problem with the increasing 32 number of patients. Available antifungal drugs are lack with their spectrum, toxic or 33 immunosuppressive in nature, so that need to develop new compound with high 34 efficacy. To evaluate antifungal efficacy of synthesized compound and to identify the 35 protein profile of Aspergillus fumigatus treated with antifungal. Clinical isolates of A. 36 fumigatus, A. flavus and A. niger were cultured and efficacy of compound were conducted 37 by Disc Diffusion Assay (DDA), Microbroth Dilution Assay (MDA). Percent of spore 38 germination inhibition assay (PSGI), Time kill analysis and toxicity assay. The culture 39 filtrate containing secretory proteins was collected after 24 h growth and expression of 40 downregulated proteins were identified. We developed a new and 41 useful quinazoline derivatives expected to antifungal activity. The result of anti-42 Aspergillus evolution revealed that one of the 3-(4-Phenyl-thiazol-2-yl)-2-thioxo-2, 3-43 dihydro-1H-quinazolin-4-one (DDVKT4Q) exhibited appreciable activity. The potency of 44 compound was found concentration of 3.125 µg/disc by disc diffusion assay (DDA) and 45 15.625 µg/ml. by Microbroth Dilution Assay (MDA). The compound was nontoxic up to 46 concentration 625 µg/ml and its lysed only 35.9% of human erythrocytes, at the 47 highest dose tested. It's observed that the treatment of pathogen with DDVKT-48 4Q targeted the expression of four proteins having molecular weights 18 kDa 37 KDa and 49 43 KDa proteins was completely inhibited or down regulated by the compound the extra 50 cellular. The novel compound DDVKT-4Q, having antifungal activity Can be exploited 51 further to develop new ideal antimycotic drugs.

